Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 387

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 15
Chunk 387
---
ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)The following documents are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K: 

1.Financial Statements: See Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K. 

2.Financial Statement Schedules: All schedules are omitted because they are not required, are not applicable or the information is included in the Consolidated Financial Statements or notes thereto. 

3.Exhibits: We have filed or incorporated by reference into this Annual Report on Form 10-K, the exhibits listed on the accompanying Exhibit Index immediately below. 

(b)Financial Statement Schedules: See Item 15(a)(2), above. 

(c)Exhibits: Refer to the Exhibit Index that follows. 

Fiscal 2024 Form 10-K130

Table of Contents

Exhibit Index

 Incorporated by reference hereinExhibitNumberDescriptionFormExhibit No.Filing Date3.1Amended and Restated Certificate of Incorporation10-K3.1March 23, 20113.2Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc. 8-K3.1November 7, 20223.3Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to declassify the Board8-K3.1June 20, 20243.4Certificate of Amendment to the Certificate of Incorporation of Pacific Biosciences of California, Inc. to limit the liability of officers8-K3.2June 20, 20244.1Specimen Common Stock CertificateS-1/A4.1October 1, 20104.2Description of Registrant’s securities registered under Section 12 of the Exchange ActFiled herewith4.3Indenture, dated February 16, 2021, between Pacific Biosciences of California, Inc., and U.S. Bank National Association, as Trustee10-Q4.1August 4, 20234.4Form of 1.50% Convertible Senior Notes due 2028 (included in Exhibit 4.3)10-Q4.1August 4, 20234.5Indenture, dated as of June 30, 2023, by and between Pacific Biosciences of California, Inc. and